LifeMD, Inc. (LFMD)

Q: What's priced into LifeMD, Inc. (LFMD) stock?

LFMD is described as cheap versus peers, but the valuation model has low confidence. The expectations gap is negative, which points to limited confidence in the current outlook; the evidence does not support a clearer estimate of what the market assumes.

Q: What does the LifeMD, Inc. (LFMD) outlook hinge on?

A favorable shift would require guidance to improve after the recent reduction, alongside continued progress toward positive adjusted EBITDA in the second half of 2026. The thesis also depends on whether healthcare-sector momentum persists; weaker employment data could increase recession concerns and pressure cyclical healthcare names.

NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-10-23

$2.13-1.84%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge LifeMD, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q3
Revenue	$48M–$51M	—
FY 2026 · Q4
Revenue	—	61.31M
EPS	—	-0.007
FY 2026 · Annual
Revenue	$205.5M–$212.5M	207.61M
EPS	—	-0.519
EBITDA	$2M–$3Mnon-GAAP	—
FY 2027 · Annual
Revenue	—	244.99M
EPS	—	-0.091

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Utilize $30M credit facility for growth initiatives	The company secured a $30M credit facility to support growth.	Intact	Credit facility remains unused or misused, failing to support growth	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Successful integration of new CTO to support growth	A new CTO appointment supports technology and growth initiatives.	Improving	CTO departure or failure to advance technology growth initiatives	Qualitative: CTO appointed Jun 2026; AT&T partnership Sep 2026 CTO Umesh Sripad appointed June 2026. AT&T partnership announced September 2026. Q2 2026 earnings beat expectations. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue growth to $220M-$230M in fiscal 2026	A primary condition in LifeMD, Inc.'s published investment case. The stated target is >= $220 million and <= $230 million.	Broken	Annual revenue falls below $220 million in FY26	Revenue: $47.281M FY2026-Q2; GAAP. Published target: >= $220 million and <= $230 million. Target period is not explicitly aligned with this observation. Source published Aug 5, 202647,281,085 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: d9c597f4-3184-4a29-ae86-5db0275a0855. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue$0.24B

$0.26B → $0.24B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$260,901,120	2 / 8
2026-07-25	Unavailable	$260,901,175	3 / 6
2026-07-26	Unavailable	$260,901,120	2 / 8
2026-07-27	Unavailable	$260,894,925	3 / 6
2026-07-28	Unavailable	$260,901,120	2 / 8
2026-07-29	Unavailable	$260,901,120	2 / 8
2026-07-30	Unavailable	$260,901,120	2 / 8
2026-07-31	Unavailable	$260,901,120	2 / 8
2026-08-01	Unavailable	$260,894,925	3 / 6
2026-08-02	Unavailable	$260,901,120	2 / 8
2026-08-03	Unavailable	$260,901,120	2 / 8
2026-08-04	Unavailable	$260,901,120	2 / 8
2026-08-05	Unavailable	$260,894,925	3 / 6
2026-08-06	Unavailable	$260,894,925	3 / 6
2026-08-07	Unavailable	$255,957,125	3 / 6
2026-08-08	Unavailable	$249,382,000	2 / 8
2026-08-09	Unavailable	$249,382,000	2 / 8
2026-08-10	Unavailable	$249,382,000	2 / 8
2026-08-12	Unavailable	$255,957,125	3 / 6
2026-08-13	Unavailable	$255,957,125	3 / 6
2026-08-14	Unavailable	$255,957,125	3 / 6
2026-08-15	Unavailable	$255,957,125	3 / 6
2026-08-16	Unavailable	$255,957,125	3 / 6
2026-08-17	Unavailable	$255,957,125	3 / 6
2026-08-18	Unavailable	$255,957,125	3 / 6
2026-08-19	Unavailable	$255,957,125	3 / 6
2026-08-20	Unavailable	$245,007,000	3 / 6
2026-08-21	Unavailable	$245,007,000	3 / 6
2026-08-22	Unavailable	$245,007,000	3 / 6
2026-08-23	Unavailable	$245,007,000	3 / 6
2026-08-24	Unavailable	$245,007,000	3 / 6
2026-08-25	Unavailable	$245,007,000	3 / 6
2026-08-26	Unavailable	$245,007,000	3 / 6
2026-08-27	Unavailable	$245,007,000	3 / 6
2026-08-28	Unavailable	$245,007,000	3 / 6
2026-08-29	Unavailable	$245,007,000	3 / 6
2026-08-30	Unavailable	$245,007,000	3 / 6
2026-08-31	Unavailable	$245,007,000	3 / 6
2026-09-01	Unavailable	$245,007,000	3 / 6
2026-09-02	Unavailable	$245,007,000	3 / 6
2026-09-03	Unavailable	$245,007,000	3 / 6
2026-09-04	Unavailable	$245,007,000	3 / 6
2026-09-05	Unavailable	$245,007,000	3 / 6
2026-09-06	Unavailable	$245,007,000	3 / 6
2026-09-07	Unavailable	$245,007,000	3 / 6
2026-09-08	Unavailable	$245,007,000	3 / 6
2026-09-09	Unavailable	$245,007,000	3 / 6
2026-09-10	Unavailable	$245,007,000	3 / 6
2026-09-11	Unavailable	$245,007,000	3 / 6
2026-09-12	Unavailable	$245,094,500	3 / 6
2026-09-13	Unavailable	$245,094,500	3 / 6
2026-09-14	Unavailable	$245,094,500	3 / 6
2026-09-15	Unavailable	$245,094,500	3 / 6
2026-09-16	Unavailable	$245,094,500	3 / 6
2026-09-17	Unavailable	$245,094,500	3 / 6
2026-09-18	Unavailable	$245,094,500	3 / 6
2026-09-19	Unavailable	$245,094,500	3 / 6
2026-09-20	Unavailable	$245,094,500	3 / 6
2026-09-21	Unavailable	$245,094,500	3 / 6
2026-09-22	Unavailable	$245,094,500	3 / 6
2026-09-23	Unavailable	$245,094,500	3 / 6
2026-09-24	Unavailable	$245,094,500	3 / 6
2026-09-25	Unavailable	$245,094,500	3 / 6
2026-09-26	Unavailable	$245,094,500	3 / 6
2026-09-27	Unavailable	$245,094,500	3 / 6
2026-09-28	Unavailable	$245,094,500	3 / 6
2026-09-29	Unavailable	$245,094,500	3 / 6
2026-09-30	Unavailable	$245,094,500	3 / 6
2026-10-01	Unavailable	$245,094,500	3 / 6
2026-10-02	Unavailable	$245,094,500	3 / 6
2026-10-03	Unavailable	$245,094,500	3 / 6
2026-10-04	Unavailable	$245,094,500	3 / 6
2026-10-05	Unavailable	$245,094,500	3 / 6
2026-10-06	Unavailable	$245,094,500	3 / 6
2026-10-07	Unavailable	$245,094,500	3 / 6
2026-10-08	Unavailable	$245,094,500	3 / 6
2026-10-09	Unavailable	$245,094,500	3 / 6
2026-10-10	Unavailable	$245,094,500	3 / 6
2026-10-11	Unavailable	$245,094,500	3 / 6
2026-10-12	Unavailable	$245,094,500	3 / 6
2026-10-13	Unavailable	$245,094,500	3 / 6
2026-10-14	Unavailable	$245,094,500	4 / 6
2026-10-15	Unavailable	$245,094,500	3 / 6
2026-10-16	Unavailable	$245,094,500	3 / 6
2026-10-17	Unavailable	$245,094,500	3 / 6
2026-10-18	Unavailable	$244,994,500	3 / 6
2026-10-19	Unavailable	$244,994,500	3 / 6
2026-10-20	Unavailable	$244,994,500	3 / 6
2026-10-21	Unavailable	$244,994,500	3 / 6
2026-10-22	Unavailable	$244,994,500	3 / 6
2026-10-23	Unavailable	$244,994,500	3 / 6
2026-10-24	Unavailable	$244,994,500	3 / 6

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	8	0	0
2026-06-01	8	0	0
2026-07-01	8	0	0
2026-08-01	8	0	0
2026-09-01	8	0	0
2026-10-01	8	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 8 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Utilize $30M credit facility for growth initiativesDirect metric needs a verified mapping
Revenue growth to $220M-$230M in fiscal 2026Published status: Broken

Next proof point

Nov 9, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.6%Typical daily move · historical

Downside history

-66.2%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

LifeMD, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-risk, loss-making growth business, with a healthcare sector backdrop that has recently improved. Its long-term thesis remains in a watch state: recent performance has lagged its industry cohort, while management’s main goals show mixed progress.

What's priced into LifeMD, Inc.

LFMD is described as cheap versus peers, but the valuation model has low confidence. The expectations gap is negative, which points to limited confidence in the current outlook; the evidence does not support a clearer estimate of what the market assumes.

What the fundamentals likely do

Near term, revenue growth and profitability remain uncertain: management cut 2026 revenue guidance and shifted its adjusted EBITDA outlook from a positive range to a loss-to-breakeven range, though quarterly adjusted EBITDA losses narrowed from Q1 to Q2. Partnerships and product launches are ongoing, but disclosed evidence on their revenue contribution is thin.

What LifeMD, Inc. hinges on